Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antihistamine study

This article was originally published in The Tan Sheet

Executive Summary

The Transportation Secretary "shall review available information on the effects of medications (including antihistamines) on driver fatigue, awareness and performance and shall consider encouraging, if appropriate, the use of nonsedating medications (including nonsedating antihistamines) as a means of reducing the adverse effects of the use of other medications by drivers," under the conference report to the transportation bill (105-555) passed by the House and Senate May 22 and signed into law (105-178) June 9. The measure potentially could benefit Claritin (loratidine) manufacturer Schering-Plough, which is understood to have backed the provision...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088524

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel